GEAP202516737A - Compounds for treating cancer - Google Patents
Compounds for treating cancerInfo
- Publication number
- GEAP202516737A GEAP202516737A GEAP202516737A GEAP2025016737A GEAP202516737A GE AP202516737 A GEAP202516737 A GE AP202516737A GE AP202516737 A GEAP202516737 A GE AP202516737A GE AP2025016737 A GEAP2025016737 A GE AP2025016737A GE AP202516737 A GEAP202516737 A GE AP202516737A
- Authority
- GE
- Georgia
- Prior art keywords
- compounds
- formula
- pharmaceutically acceptable
- acceptable salts
- treating cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263406081P | 2022-09-13 | 2022-09-13 | |
| US202263419451P | 2022-10-26 | 2022-10-26 | |
| US202263435170P | 2022-12-23 | 2022-12-23 | |
| US202363536249P | 2023-09-01 | 2023-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202516737A true GEAP202516737A (en) | 2025-06-10 |
Family
ID=88237760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202516737A GEAP202516737A (en) | 2022-09-13 | 2023-09-11 | Compounds for treating cancer |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP4568948A1 (fr) |
| JP (1) | JP2025530333A (fr) |
| KR (1) | KR20250067170A (fr) |
| CN (1) | CN120112518A (fr) |
| AU (1) | AU2023342774A1 (fr) |
| CA (1) | CA3264256A1 (fr) |
| CL (1) | CL2025000672A1 (fr) |
| CO (1) | CO2025003099A2 (fr) |
| CR (1) | CR20250124A (fr) |
| DO (1) | DOP2025000057A (fr) |
| GE (1) | GEAP202516737A (fr) |
| IL (1) | IL319513A (fr) |
| JO (1) | JOP20250057A1 (fr) |
| MA (1) | MA71734A (fr) |
| MX (1) | MX2025002817A (fr) |
| PE (1) | PE20251692A1 (fr) |
| TW (1) | TW202426427A (fr) |
| WO (1) | WO2024059010A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202854A1 (fr) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Inhibiteurs de cdk4 et combinaisons avec des inhibiteurs de cdk2 ou d'autres agents destinés à être utilisés dans le traitement du cancer |
| WO2025240536A1 (fr) * | 2024-05-15 | 2025-11-20 | Nikang Therapeutics, Inc. | Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante d'une cycline et/ou la kinase 4 dépendante d'une cycline par l'intermédiaire de la voie ubiquitine-protéasome |
| WO2026024674A1 (fr) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Méthodes de traitement de cancers associés à skp2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100874791B1 (ko) * | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도 |
| CN115297861B (zh) | 2020-01-29 | 2024-07-12 | 福宏治疗公司 | 化合物及其用途 |
| WO2022105771A1 (fr) | 2020-11-17 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | Dérivé hétérocyclique azoté, son procédé de préparation et son application médicale |
| WO2022135365A1 (fr) * | 2020-12-22 | 2022-06-30 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Inhibiteurs de kinase de cyclopentane disubstitués |
| TW202246255A (zh) | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
-
2023
- 2023-09-11 GE GEAP202516737A patent/GEAP202516737A/en unknown
- 2023-09-11 EP EP23783180.5A patent/EP4568948A1/fr active Pending
- 2023-09-11 JP JP2025515376A patent/JP2025530333A/ja active Pending
- 2023-09-11 MA MA71734A patent/MA71734A/fr unknown
- 2023-09-11 CA CA3264256A patent/CA3264256A1/fr active Pending
- 2023-09-11 WO PCT/US2023/032420 patent/WO2024059010A1/fr not_active Ceased
- 2023-09-11 KR KR1020257011828A patent/KR20250067170A/ko active Pending
- 2023-09-11 CR CR20250124A patent/CR20250124A/es unknown
- 2023-09-11 AU AU2023342774A patent/AU2023342774A1/en active Pending
- 2023-09-11 PE PE2025000541A patent/PE20251692A1/es unknown
- 2023-09-11 IL IL319513A patent/IL319513A/en unknown
- 2023-09-11 CN CN202380074814.7A patent/CN120112518A/zh active Pending
- 2023-09-12 TW TW112134698A patent/TW202426427A/zh unknown
-
2025
- 2025-03-10 MX MX2025002817A patent/MX2025002817A/es unknown
- 2025-03-10 DO DO2025000057A patent/DOP2025000057A/es unknown
- 2025-03-11 CO CONC2025/0003099A patent/CO2025003099A2/es unknown
- 2025-03-11 CL CL2025000672A patent/CL2025000672A1/es unknown
- 2025-03-12 JO JOJO/P/2025/0057A patent/JOP20250057A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025000672A1 (es) | 2025-07-11 |
| CN120112518A (zh) | 2025-06-06 |
| MX2025002817A (es) | 2025-04-02 |
| JOP20250057A1 (ar) | 2025-03-12 |
| AU2023342774A1 (en) | 2025-02-27 |
| MA71734A (fr) | 2025-05-30 |
| CA3264256A1 (fr) | 2024-03-21 |
| PE20251692A1 (es) | 2025-07-02 |
| KR20250067170A (ko) | 2025-05-14 |
| TW202426427A (zh) | 2024-07-01 |
| EP4568948A1 (fr) | 2025-06-18 |
| JP2025530333A (ja) | 2025-09-11 |
| DOP2025000057A (es) | 2025-04-08 |
| CO2025003099A2 (es) | 2025-03-27 |
| WO2024059010A1 (fr) | 2024-03-21 |
| CR20250124A (es) | 2025-05-07 |
| IL319513A (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| WO2022125616A8 (fr) | Tryptamines de dialkyle et leurs utilisations therapeutiques | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PH12022552261A1 (en) | Crystalline hydrate of a jak inhibitor compound | |
| MX2024000299A (es) | Compuestos antivirales. | |
| WO2021147236A9 (fr) | Utilisation d'un composé d'aminopropionate substitué dans le traitement d'infections provoquées par le sars-cov-2 | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| MX2022006990A (es) | Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| MX2024003459A (es) | Metodos de tratamiento de trastornos metabolicos. | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| MX2025011458A (es) | Inhibidor de cyp11a1 y uso del mismo | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| MX2025002452A (es) | Serie de compuestos heterociclicos puenteados que contienen nitrogeno y metodo de preparacion de los mismos | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| MX2024009608A (es) | Compuestos heterociclicos y metodos de uso. | |
| GEAP202516749A (en) | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives | |
| MX2025006291A (es) | Metodos de tratamiento de trastornos neurologicos | |
| MX2025001642A (es) | Tratamiento del cancer de piel | |
| WO2025188946A8 (fr) | Inhibiteurs de wee1 et méthodes de traitement du cancer | |
| MX2025000498A (es) | Formas sólidas de un derivado de triazina como modulador del gen oncogénico de linfoma b de casitas (cbl-b). |